Copyright
©2009 The WJG Press and Baishideng.
World J Gastroenterol. Jan 21, 2009; 15(3): 328-333
Published online Jan 21, 2009. doi: 10.3748/wjg.15.328
Published online Jan 21, 2009. doi: 10.3748/wjg.15.328
Characteristics | Total group (n = 301) |
Age1 (yr) | 48.27 ± 11.79 |
Gender (%, M/F) | 57.5/42.5 |
Contamination mode (%) | |
Tranfusion | 27.2 |
Drug-addict | 26.9 |
Blood exposure accident | 7.6 |
Others | 38.2 |
Genotype (% with 1/2/3/4/5/ND) | 35/11/18/8/2/26 |
Stage of fibrosis (% with stage 0/1/2/3/4/ND) | 1/11/42/20/20/6 |
Type of treatment (%) | |
With IFNα | 3.3 |
Peg-interferon | 9.0 |
IFNα + ribavirin | 27.2 |
Peg-interferon + ribavirin | 60.4 |
Duration of treatment (mo)1 | 7.91 ± 3.78 |
TSH before treatment (MIU/L)1 | 1.54 ± 1.25 |
Positive antibodies before treatment | |
TPOAb | 12/229 |
TGAb | 8/227 |
TSHRAb | 1/95 |
- Citation: Gelu-Simeon M, Burlaud A, Young J, Pelletier G, Buffet C. Evolution and predictive factors of thyroid disorder due to interferon alpha in the treatment of hepatitis C. World J Gastroenterol 2009; 15(3): 328-333
- URL: https://www.wjgnet.com/1007-9327/full/v15/i3/328.htm
- DOI: https://dx.doi.org/10.3748/wjg.15.328